Showing results (411-420 of 427) with videos related to

Sort By:
Pageof 43
The Lancet. Oncology|October 16, 2022
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 studyZev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2026
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction CancerIzuma Nakayama, Min-Hee Ryu, Sung Hee Lim, et al.
Cancer Research and Treatment|October 14, 2025
Real World Efficacy of 1st-Line Nivolumab Plus Ipilimumab and its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13)Jwa Hoon Kim, Sang Joon Shin, Woo Kyun Bae, et al.
Cancer Research and Treatment|July 3, 2025
Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4)Yoon-Koo Kang, Min-Hee Ryu, Do-Youn Oh, et al.
Therapeutic Advances in Medical Oncology|September 23, 2021
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)Hye Sook Han, Bum Jun Kim, Hee-Jung Jee, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 3, 2022
Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY studyHyung-Don Kim, Jong Seok Lee, Young Soo Park, et al.
BMC Cancer|February 23, 2024
Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)Sung Hee Lim, Keun-Wook Lee, Jae-Joon Kim, et al.
Cancer Research and Treatment|December 14, 2021
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking GroupShinkyo Yoon, Miso Kim, Yong Sang Hong, et al.
The American Journal of Gastroenterology|February 2, 2023
A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneDo Young Kim, Yu Ri Kim, Cheolwon Suh, et al.
The Korean Journal of Internal Medicine|February 9, 2021
2020 Korean guidelines for the management of metastatic prostate cancerIn-Ho Kim, Sang Joon Shin, Byung Woog Kang, et al.
Pageof 43